Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials

Jendle, Johan; Birkenfeld, Andreas L.; Polonsky, William H.; Silver, Robert J.; Uusinarkaus, Kari; Hansen, Thomas K.; Håkan‐Bloch, Jonas; Tadayon, Sayeh; Davies, Melanie J.

doi:10.1111/dom.13816

Cited by 12 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, in most SUSTAIN trials, patients on semaglutide reported better overall treatment satisfaction over comparators. 27 Along with increased patient satisfaction, the approval of Wegovy as a weight loss medication could result in more avenues to investigate the many underlying mechanisms of weight loss by GLP-1 RAs. Presently, most animal and human studies exploring these mechanisms have been conducted using liraglutide.…”

Section: Summary Of Sustain Evidencementioning

confidence: 99%

See 1 more Smart Citation

Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management

Singh

Krauthamer

Bjalme-Evans

2022

Journal of Investigative Medicine

109

View full text Add to dashboard Cite

Obesity is a growing epidemic within the USA. Because weight gain is associated with an increased risk of developing life-threatening comorbidities, such as hypertension or type 2 diabetes, there is great interest in developing non-invasive pharmacotherapeutics to help combat obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic medications that have shown promise in encouraging glycemic control and promoting weight loss in patients with or without type 2 diabetes. This literature review summarizes and discusses the weight loss results from the SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes), PIONEER (Peptide Innovation for Early Diabetes Treatment), and STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programs. The SUSTAIN and PIONEER clinical trials studied the use of 1.0 mg, once-weekly, subcutaneous and oral semaglutide (a new GLP-1 homolog), respectively, on participants with type 2 diabetes. The STEP trial examined the effects of 2.4 mg, once-weekly, subcutaneous semaglutide on patients with obesity. Trial data and other pertinent articles were obtained via database search through the US National Library of Medicine Clinical Trials and the National Center for Biotechnology Information. All three clinical trials demonstrated that semaglutide (injected or oral) has superior efficacy compared with placebo and other antidiabetic medications in weight reduction, which led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss.

show abstract

Section: Summary Of Sustain Evidencementioning

confidence: 99%

“…In fact, in most SUSTAIN trials, patients on semaglutide reported better overall treatment satisfaction over comparators. 27 …”

Section: Summary Of Sustain Evidencementioning

confidence: 99%

Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management

Singh

Krauthamer

Bjalme-Evans

2022

Journal of Investigative Medicine

109

View full text Add to dashboard Cite

show abstract

“…Additionally, CV benefits and positive effects on some kidney outcomes have been shown with OW semaglutide in participants with T2D 22,23 . Compared with BBI, the lower number of injections required with OW semaglutide may also enhance treatment adherence and QoL 8,24,25 …”

Section: Introductionmentioning

confidence: 99%

Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial

Kellerer

Kaltoft

Lawson

et al. 2022

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim To compare the efficacy and safety of once‐weekly (OW) semaglutide versus thrice‐daily (TID) insulin aspart (IAsp) in participants with inadequately controlled type 2 diabetes (T2D) treated with insulin glargine (IGlar) and metformin. Materials and Methods SUSTAIN 11 (NCT03689374) was a randomized (1:1), parallel, open‐label, multinational, phase 3b trial. After a 12‐week run‐in to optimize once‐daily IGlar U100, 1748 adults with T2D (HbA1c >7.5% to ≤10.0%) were randomized to OW semaglutide or TID IAsp as add‐on to optimized IGlar and metformin for 52 weeks. The primary outcome was change in HbA1c from randomization to week 52. Confirmatory secondary endpoints included the occurrence of severe hypoglycaemic episodes and change in body weight (BW). Safety was assessed. Results HbA1c (randomization: 8.6% [70.0 mmol/mol]) decreased by 1.5% points (16.6 mmol/mol) and 1.2% points (13.4 mmol/mol) with semaglutide (n = 874) and IAsp (n = 874), respectively (estimated treatment difference [ETD] −0.29% points [95% confidence interval {CI} −0.38; −0.20]; P < .0001 for non‐inferiority). Few severe hypoglycaemic episodes were recorded in either group, with no statistically significant difference between the groups. Change in BW from randomization (87.9 kg) to week 52 was in favour of semaglutide (−4.1 kg) versus IAsp (+2.8 kg) (ETD −6.99 kg [95% CI −7.41; −6.57]). A higher proportion of participants experienced adverse events with semaglutide (58.5%) versus IAsp (52.1%); most were mild to moderate. Conclusions In this basal insulin‐treated population, OW semaglutide improved glycaemic control to a greater extent than TID IAsp and provided numerically greater weight loss.

show abstract

“…Patient-reported outcomes assess psychological aspects such as treatment satisfaction, patient wellbeing, health status, and quality of life to complement clinical outcomes and provide an understanding of the physical, social, and emotional impact of treatment regimens (36). For the SUSTAIN trials shown, estimated mean changes from baseline in body weight included only data obtained before initiation of any rescue medication or before premature treatment discontinuation.…”

Section: Patient-reported Outcomesmentioning

confidence: 99%

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation

Meier

2021

Front. Endocrinol.

View full text Add to dashboard Cite

Despite the benefits of early and effective glycemic control in the management of type 2 diabetes (T2D), achieving glycated hemoglobin (HbA1c) targets is challenging in some patients. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide effective reductions in HbA1c and body weight. Semaglutide is the only GLP-1RA that is available in both an injectable and oral formulation. The efficacy of once-weekly subcutaneous semaglutide and once-daily oral semaglutide has been investigated in the global SUSTAIN and PIONEER phase III clinical trial programs in a range of clinical settings, including early T2D managed with diet and exercise only, more established T2D uncontrolled on one to three oral antidiabetic drugs, and advanced disease treated with insulin. Across the SUSTAIN program, once-weekly subcutaneous semaglutide 1.0 mg reduced HbA1c by 1.5–1.8% after 30–56 weeks, which was significantly more than sitagliptin, liraglutide, exenatide extended release, dulaglutide, canagliflozin, or insulin glargine. Across the PIONEER program, once-daily oral semaglutide 14 mg reduced HbA1c by 1.0–1.4%, significantly more than sitagliptin or empagliflozin, and to a similar extent as liraglutide after 26 weeks. In addition, subcutaneous semaglutide reduced body weight significantly more than all active comparators tested, while oral semaglutide reduced body weight more than sitagliptin and liraglutide, and to a similar extent as empagliflozin. Neither formulation of semaglutide has been associated with an increased risk of hypoglycemia and both improve various measures of health-related quality of life. Semaglutide offers the benefits of a highly effective GLP-1RA in both injectable and oral formulations. Selection of the most appropriate formulation can be made on an individual basis to best suit the patient’s preferences and needs.

show abstract

Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials

Cited by 12 publications

References 38 publications

Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management

Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management

Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation

Contact Info

Product

Resources

About